Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 10/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.48 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL4860806 | 1.00 | GRIK1 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL7781242 | 0.95 | GRIK1 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL28135367 | 0.95 | GRIK1 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL305805 | 0.95 | GRIK1 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL305804 | 0.95 | GRIK1 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL7781246 | 0.95 | GRIK1 (0.58) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL8099944 | 0.92 | GRIK1 (0.56) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL8092320 | 0.92 | GRIK1 (0.56) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL7204819 | 0.92 | SLC7A5 (0.56) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL8383423 | 0.92 | SLC7A5 (0.56) | GRIK1SLC7A5GRIK2GRM1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227976-A1 | PROCESS FOR SYNTHESIZING ASPARTIC AND GLUTAMIC ACID DERIVATIVES ESPECIALLY USEFUL AS INTERMEDIATES IN THE MANUFACTURE OF A CASPASE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATEAD (US) | 2008-09-18 | — | — | US | disclosed |
| US-7335792-B2 | Process for synthesizing aspartic and glutamic acid derivatives especially useful as intermediates in the manufacture of a caspase inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1436248-A2 | PROCESS FOR SYNTHESIZING ASPARTIC AND GLUTAMIC ACID DERIVATIVES AND DIAZOKETONE INTERMEDIATES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030162993-A1 | Process for synthesizing aspartic and glutamic acid derivatives especially useful as intermediates in the manufacture of a caspase inhibitor | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-28 | — | — | US | disclosed |
| WO-2003042169-A2 | PROCESS FOR SYNTHESIZING ASPARTIC AND GLUTAMIC ACID DERIVATIVES AND DIAZOKETONE INTERMEDIATES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162993-A1 | Process for synthesizing aspartic and glutamic acid derivatives especially useful as intermediates in the manufacture of a caspase inhibitor | CASP1, CASP5, CASP2 | GRIK1 78/4885SLC7A5 1628/4885GRIK2 102/4885 |
| US-20080227976-A1 | PROCESS FOR SYNTHESIZING ASPARTIC AND GLUTAMIC ACID DERIVATIVES ESPECIALLY USEFUL AS INTERMEDIATES IN THE MANUFACTURE OF A CASPASE INHIBITOR | CASP1, CASP5, CASP2 | GRIK1 78/4885SLC7A5 1628/4885GRIK2 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.